Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × vosaroxin × Clear all
NCT00246662 2017-03-30

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Sunesis Pharmaceuticals

Phase 1 Completed
75 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00091585 2007-05-10

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Sunesis Pharmaceuticals

Phase 1 Completed
Tumor-Agnostic

Neoplasms

NCT00094159 2007-05-10

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

Sunesis Pharmaceuticals

Phase 1 Completed
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡